收藏切换
Recent advances in clinical research of anti-fibrotic therapy for progressive pulmonary fibrosis
收藏切换
Yanyan ZENG1, Siqian PENG1, Yan ZHENG2, Qihang YU2, Na NI1, *, Junlong Wang1, *
World Clinical Drug | 2025, 46(11) : 1181 - 1187
Less
收藏切换
World Clinical Drug | 2025, 46(11): 1181-1187
• Review •
Recent advances in clinical research of anti-fibrotic therapy for progressive pulmonary fibrosis
Full
Yanyan ZENG1, Siqian PENG1, Yan ZHENG2, Qihang YU2, Na NI1, *, Junlong Wang1, *
Affiliations
  • 1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
  • 2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China
Published: 2025-11-10 doi: 10.13683/j.wph.2025.11.014
Outline
收藏切换

In 2022, the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association jointly released a clinical practice guideline that introduced the term progressive pulmonary fibrosis (PPF) to collectively refer to the progressive fibrotic phenotypes of interstitial lung diseases other than idiopathic pulmonary fibrosis (IPF). These diseases may exhibit clinical course characteristics and core mechanisms of fibrosis similar to those of IPF, even after standardized treatment. Currently, the two anti-fibrotic drugs nintedanib and pirfenidone approved by the U.S. Food and Drug Administration, can only slow the decline in lung function in patients with IPF, but cannot reverse fibrosis. Due to the significant heterogeneity of PPF patient population and complex enrollment criteria, clinical trials targeting PPF often terminate due to recruitment challenges. Consequently, current drug development strategies primarily select IPF as the initial indication and then gradually expand to other fibrotic lung diseases after confirming effectiveness. In the research and development pipeline, most candidate drugs remain in the early stages of clinical development, with only a few advancing to phase Ⅱ/Ⅲ clinical studies and simultaneously exploring the PPF indication. Notably, in 2024, the world's first anti-fibrotic drug designed entirely using artificial intelligence (AI), INS018-055, successfully progressed to Phase Ⅱ clinical trials, marking a significant breakthrough application of AI technology in drug development. This article systematically dissected the conceptual framework of PPF, covering its definition, disease spectrum, epidemiological characteristics, and molecular mechanisms, while reviewed the latest clinical research advancements from the perspective of anti-fibrotic treatment, aiming to provide a theoretical foundation for the discovery of new targets and translational research.

idiopathic pulmonary fibrosis  /  progressive pulmonary fibrosis  /  pulmonary fibrosis  /  antifibrotic therapy  /  artificial intelligence
曾艳艳, 彭思芊, 郑岩, 于启航, 倪娜, 王俊龙. 进展性肺纤维化抗纤维化治疗的临床研究新进展. 世界临床药物, 2025 , 46 (11) : 1181 -1187 . DOI: 10.13683/j.wph.2025.11.014
Yanyan ZENG, Siqian PENG, Yan ZHENG, Qihang YU, Na NI, Junlong Wang. Recent advances in clinical research of anti-fibrotic therapy for progressive pulmonary fibrosis[J]. World Clinical Drug, 2025 , 46 (11) : 1181 -1187 . DOI: 10.13683/j.wph.2025.11.014
Year 2025 volume 46 Issue 11
51
12
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2025.11.014
  • Receive Date:2025-03-24
  • Online Date:2026-11-09
  • Published:2025-11-10
Article Data
Affiliations
History
  • Received:2025-03-24
Affiliations
    1.Clinical Research Center, China State Institute of Pharmaceutical Industry, Shanghai 200437, China
    2.Shanghai InnoClinic Pharmaceutical Development Co, Ltd., Shanghai 200437, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.11.014
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT